Trimble Partners with Microsoft to Bring Microsoft HoloLens Wearable Holographic Technology to the AEC Industry

SAN FRANCISCO, April 29, 2015 /PRNewswire/ -- Trimble (NASDAQ: TRMB) announced today that it is working with Microsoft to develop a new generation of tools, integrated with the HoloLens holographic platform on Windows 10, which are intended to improve quality, collaboration and efficiency in the design, construction and operation of buildings and structures. A proof of concept was demonstrated at Microsoft's Build Developer Conference held this week in San Francisco. 

Microsoft HoloLens is a head-mounted, holographic computer that provides a mixed-reality experience for a range of commercial and consumer applications. When used by architecture, engineering and construction (AEC) professionals, the HoloLens device extends interaction with 3D models beyond the confines of a 2D computer screen, creating new ways for the many stakeholders of complex, multi-phase construction projects to visualize, collaborate, share ideas and manage change. 

Demonstration Highlights Design and Collaboration Scenarios

During the Build Conference keynote session, Microsoft demonstrated how the integration of HoloLens with Trimble's SketchUp 3D modeling software and the Trimble Connect collaboration platform could improve design and construction processes. Using HoloLens, architects were able to experience their SketchUp models as holograms placed in the real world—enabling them to quickly analyze various "what if" design scenarios in the context of the physical environment. The demonstration also illustrated how using Trimble Connect with HoloLens holographic technology enables remote teams to effectively review and collaborate in order to resolve constructability issues in real time. 

A recording of the demonstration is available at:  www.buildwindows.com. Additional information on the Trimble and Microsoft collaboration is available at:  http://buildings.trimble.com/hololens.   

"Trimble has a mission to deliver solutions that transform the user experience and work processes in many industries," said Bryn Fosburgh, vice president responsible for Trimble's Construction Technology Divisions. "We believe that HoloLens is a game-changer for design and construction teams by facilitating improved communication, and enhanced transparency. We're excited to partner with Microsoft in creating what could be a new era for technology in the AEC market."

"Microsoft HoloLens is a revolutionary tool for people and businesses enabling professionals in industries like design and construction to do more and achieve more," said Yusuf Mehdi, corporate vice president, devices & studios, at Microsoft. "Trimble's deep knowledge of design and construction processes makes it a natural partner in bringing holographic computing to this industry." 

Initial Development Focus

Trimble's initial research is focused on the integration of HoloLens with three Trimble solutions: 

• Trimble® Connect – a collaboration environment for design, engineering and construction projects, based on Gehry Technologies' GTeam™ software acquired by Trimble in in 2014, Trimble Connect enables teams to access and manage project data via a cloud platform. 
• SketchUp – the world's most popular 3D modeling platform, used by millions around the world to create, update and communicate designs in 3D. 
• Trimble V10 Imaging Rover – an integrated camera system that precisely captures 360-degree digital panoramas for efficient visual documentation and measurement of the surrounding environment that can be transformed into data-rich geospatial deliverables.

Trimble's HoloLens-enabled solutions are currently under development. Details on availability were not disclosed at the Build Conference. Information on Trimble's broad range of existing solutions for the design, construction and operation of building and infrastructure is available at: http://www.trimble.com/Industries/Construction/index.aspx. 

About Trimble

Trimble applies technology to make field and mobile workers in businesses and government significantly more productive. Solutions are focused on applications requiring position or location—including surveying, construction, agriculture, fleet and asset management, public safety and mapping. In addition to utilizing positioning technologies, such as GPS, lasers and optics, Trimble solutions may include software content specific to the needs of the user. Wireless technologies are utilized to deliver the solution to the user and to ensure a tight coupling of the field and the back office. Founded in 1978, Trimble is headquartered in Sunnyvale, Calif. 

For more information, visit: www.trimble.com. 

GTRMB

SOURCE Trimble


RELATED LINKS
http://www.trimble.com

---

Energy Sector Volume Sizzlers – Exxon Mobil (XOM), Chevron (CVX), Schlumberger (SLB), Total SA (ADR) (TOT), Halliburton (HAL)

Energy shares were elevated in pre-market trade Wednesday as crude oil futures gained. Light, sweet crude oil for March delivery moved to higher value of 0.3% at $46.72 per barrel. In other energy outlooks, heating oil was up 0.5% at $1.59 per gallon while natural gas was up 5.2% at $2.78 British thermal units.

Exxon Mobil Corporation (NYSE:XOM) remained a volume gainer of 2.75 million shares and the average volume of the stock remained 17.38 million shares. The stock opened the session at $91.74 and was recently trading at $91.58 and the stock escalated 0.54%. Exxon Mobil Corporation (NYSE:XOM) recently declared that production has started at the Sakhalin-1 project’s Arkutun-Dagi field – the last of the three fields to be developed. Peak daily production from the field is expected to reach 90,000 barrels. The field, located off the northeast coast of Sakhalin Island in the Russian Far East, will bring total daily production at Sakhalin-1 to more than 200,000 barrels. The other two fields – Chayvo and Odoptu – began production in 2005 and 2010, correspondingly.

Exxon Mobil Corporation (NYSE:XOM), explores and produces for crude oil and natural gas. As of December 31, 2013, the company had approximately 37,661 gross and 31,823 net operated wells.

In the recent trading session, Chevron Corporation (NYSE:CVX) exchanged 1.98 million shares and the average volume remained 10.33 million shares. The stock, in the current trading session, was at $107.46, with the gain of 0.93%. Chevron Corporation (NYSE:CVX) recently declared its Australian subsidiaries have entered into a binding Sales and Purchase Agreement (SPA) with SK LNG Trading Pte Ltd (SK). Under the SPA, SK LNG Trading, which is part of a leading industrial conglomerate in South Korea, will receive 4.15 million tons of LNG over a five-year period opening in 2017.

Chevron Corporation (NYSE:CVX), through its subsidiaries, is engaged in petroleum, chemicals, mining, power generation, and energy operations worldwide. The company operates in two segments, Upstream and Downstream.

Schlumberger Limited (NYSE:SLB) enhanced 1.55% and its trading price was $81.73 recently. The volume of the stock was 2.08 million shares and the average volume remained 10.41 million shares. Schlumberger Limited (NYSE:SLB) recently reported results for the full-year and fourth-quarter 2014. Schlumberger CEO Paal Kibsgaard commented, “Full-year 2014 income of $48.6 billion amplified 7% year-on-year and grew for the fifth consecutive year. Performance was driven by North America where income grew 16%, while International Area growth of 4% was led by a 10% increase in Middle East & Asia Area revenue. Full-year pretax operating income grew by 13%, with pretax operating margin mounting 113 basis points to 21.8%. International margin expanded by 168 basis points to reach 23.9%, reflecting an incremental operating margin of 69%.

Schlumberger Limited (NYSE:SLB), together with its subsidiaries, supplies technology, integrated project management, and information solutions to oil and gas exploration and production industries worldwide.

Total SA (ADR) (NYSE:TOT) exchanged 2.41million shares in the recent trading session, and its average trading remained 2.36 million shares. TOT advanced 2.75% and was trading at $51.65. Total SA (ADR) (NYSE:TOT) has initiated gas and condensate production from the West Franklin Phase 2 project in the Central Graben area of the UK North Sea. The project will supply 40,000 barrels of oil equivalent per day (boe/d) to the Elgin/Franklin hub. “With the start-up of the West Franklin Phase 2 project, Total consolidates the production capacity of its operated Elgin/Franklin hub. The hub holds major reserves as well as promising exploration opportunities”, outlined Michael Borrell, Total’s Senior Vice President Exploration & Production, Europe and Central Asia.

Total SA (ADR) (NYSE:TOT), together with its subsidiaries, operates as an oil and gas company worldwide. The company operates in three segments: Upstream, Refining & Chemicals, and Marketing & Services.

Halliburton Company (NYSE:HAL) remained a volume gainer of 4.83 million shares and the average volume of the stock remained 22.30 million shares. The stock opened the session at $40.23 and was recently trading at $40.77and the stock escalated 2.33%. Halliburton Company (NYSE:HAL) declared that revenue from ongoing operations for the fourth quarter of 2014 was $1.0 billion, or $1.19 per diluted share, exclusive of restructuring charges of $90 million, after-tax, or $0.11 per diluted share, and Baker Hughes acquisition-related costs of $19 million, after-tax, or $0.02 per diluted share. This contrasts to income from ongoing operations for the third quarter of 2014 of $1.0 billion, or $1.19 per diluted share, excluding Macondo-related items.

Halliburton Company (NYSE:HAL) provides a range of services and products for the exploration, development, and production of oil and natural gas to oil and gas companies worldwide.

source: http://www.wsnewspublishers.com/basic-material/volume-sizzlers-exxon-mobil-xom-chevron-cvx-schlumberger-slb-total-sa-adr-tot-halliburton-hal/

Biotechnology Stocks News Review-Avalanche Biotechnologies (AAVL), Arca Biopharma (ABIO), ACADIA Pharmaceuticals (ACAD), Achillion Pharmaceuticals, (ACHN)

The presence of Sciences explanation's rundown of biotech little top stocks to watch in 2015 imprints the third year a group of experts has come commonly to incorporate a bushel of stocks focused around impetus standpoints for the New Year. Biotech financial specialists are an idealistic parcel, so in a boiling over buyer business like the one the division's been surviving for as long as two or more years, talk of valuation bloat subsides into the separation. Barclays Analyst Sees Biotech FY15 EPS Growth Outstripping Market The biotech area's evaluated 2015 income improvement of 19% will far outpace the more extensive business while prescription repayment rates will stay solid, an examiner. These biotech stocks are balanced for occasions of change, which perusers can screen year-round progressively utilizing the Portfolio Tracker. Biotech Showcase actively present people can hear the experts' contemplations on these biotech stocks at a restrictive board discourse on Jan. 13 or sign up beneath to get a rundown of the discussions and upgrades on an organization's advancement as the year progressed. Despite the fact that the wide market picks up left victors in just about every corner of the U.S. economy, the Biotech division emerged unmistakably as a star entertainer of the year. The NASDAQ Biotechnology file conveyed a stellar 34% return in 2014 - developing as the greatest victor among all the segments.

Avalanche Biotechnologies Inc(NASDAQ:AAVL) a clinical-stage biotechnology organization concentrated on finding and creating novel quality treatments to change the lives of patients with sight-debilitating ophthalmic sicknesses, affirmed the estimating of its open offering of 2,399,457 shares of its basic stock at an open offering cost of $59.00 every offer, before guaranteeing rebates, commissions and assessed costs. 2,009,457 of the shares of basic stock are being offered by Avalanche and 390,000 of the shares are being offered by existing stockholders. The EPS growth this year was -212.50% while the EPS growth prior year was 33.20%. The company has $1.32B market capitalizations and the institutional ownership was 66.70%. AAVL published that it documented an enlistment proclamation on Form S-1/A with the Securities and Exchange Commission identifying with a proposed open offering of 2,000,000 shares of its regular stock. This take after on offering is relied upon to comprise of 1,762,500 shares to be offered by Avalanche and 237,500 shares to be offered by existing stockholders. Also, the guarantors have been allowed a 30-day choice to buy up to an extra 300,000 shares from the offering shareholders and Avalanche.

A biopharmaceutical organization Arca Biopharma Inc(NASDAQ:ABIO) creating hereditarily focused on helps for cardiovascular infections, promulgated the initiation of the first GENETIC-AF medical trial site in Canada. This site brings the aggregate current number of dynamic trial destinations to thirty-three. ABIO has Insider Ownership of 1.90% and its EPS growth this year was 46.40%. offered  Annual EPS growth prior past year was 63.20%. ARCA arrangements to enact an aggregate of pretty nearly 60 clinical trial locales in the United States and Canada for the Phase 2b parcel of the trial.

ACADIA Pharmaceuticals Inc.(NASDAQ:ACAD) concentrated on creative medications that address unmet therapeutic needs in neurological and related focal sensory system issue, affirmed that it will introduce at the 33rd yearly J.p. Morgan Healthcare symposium on Tuesday, January 13, 2015, that will be commence at 11:30 a.m. Pacific Time in San Francisco. ACADIA Pharmaceuticals has market capitalization was 3.33B while EPS in next five years is expected to reach 20.00%.The company has has the institutional ownership of 95.30%. NUPLAZID is ACADIA's restrictive little atom that is a specific serotonin converse agonist specially focusing on 5-Ht2a receptors that assume a critical part in psychosis. ACADIA has reported positive Phase III trial results with NUPLAZID, which can possibly be the first medication affirmed in the United States for psychosis connected with Parkinson's ailment. The company has quarterly revenue growth of -93.80% while its short interest share was 18.34%.

Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) disclosed 100 percent Svr4 results from the progressing six-week trial. This study is a without interferon, without ribavirin, Phase 2 open-name, randomized study to assess the viability, security, and mediocrity of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a promoted nucleotide polymerase inhibitor, once every day, in treatment-innocent genotype 1 HCV-contaminated patients. The company offered 17.58% EPS for prior five years. The company has $1.46B market capitalizations and the institutional ownership was 90.70%. Its price to book ratio was 1.21. Volatility of the week stock was 7.62% and for the month stock was 8.88%.

OmniVision and Wavelens Bring MEMS-Based High-Speed Autofocus to Next-Generation Smartphones

LAS VEGAS, Jan. 9, 2015 /TRENDINGGLOBALNEWS/ -- OmniVision Technologies, Inc. (NASDAQ: OVTI), a leading developer of advanced digital imaging solutions, recently announced from the Consumer Electronics Show in Las Vegas, that it has partnered with Wavelens to bring to market an innovative autofocus (AF) technology that utilizes a microelectromechanical system (MEMS) instead of the dated voice coil motor (VCM) technology used in many consumer devices today. OmniVision couples its 23.8-megapixel OV23850 sensor with Wavelens' solution to provide MEMS-based, high-speed autofocus functionality with DSC-like image quality and performance for flagship smartphones.

"With our partnership with OmniVision, we are able to fully leverage the high-speed focus and low-power consumption that our MEMS-based autofocus technology offers," said Sebastien Bolis, CEO at Wavelens. "Together, we are redefining what users can do with a smartphone camera, allowing them to take rapid multi-frame captures or to have continuous autofocus during video capturing." 

"The OV23850 supports fast-auto focus modes and is our highest resolution image sensor currently available, which makes it the preferred sensor for the MEMS focus technology developed by Wavelens," said Tehzeeb Gunja, senior partnership and business development manager at OmniVision. "VCM-based autofocus, while a proven technology, suffers from slow speed to focus and high current consumption. We are excited to take part in the transition to a superior MEMs-based solution that can overcome VCM's shortcomings. OmniVision is working with Wavelens to bring to market the MEMS-based autofocus technology across a wide array of sensors."

The OV23850 is capable of recording quad high definition (QHD) video at 30 FPS in HDR mode to enable 'always on' HDR preview mode for a resolution size popular with flagship smartphone displays. Additionally, the sensors support 720p HD video at 120 FPS and 1080p HD video at 90 FPS, allowing for crisp slow motion video recording.

About OmniVision OmniVision Technologies (NASDAQ: OVTI) is a leading developer of advanced digital imaging solutions. Its award-winning CMOS imaging technology enables superior image quality in many of today's consumer and commercial applications, including mobile phones, notebooks, tablets and webcams, digital still and video cameras, security and surveillance, entertainment devices, automotive and medical imaging systems. Find out more at www.ovt.com. 

About WAVELENS Wavelens is developing optical MEMS solutions aimed at improving cameras image quality by making easier the integration of optical functions such as Autofocus, Image Stabilization and Zoom. Wavelens is leveraging a disruptive microsystem technology to provide its customers with a competitive products offer relying on compact MEMS outline, high speed and extremely low power consumption whatever the camera resolution. Find out more at www.wavelens.com. 

Safe-Harbor Language Certain statements in this press release, including statements regarding the expected benefits, performance, capabilities, and potential market appeal of the OV23850 are forward-looking statements that are subject to risks and uncertainties. These risks and uncertainties, which could cause the forward-looking statements and OmniVision's results to differ materially, include, without limitation: potential errors, design flaws or other problems with OV23850, customer acceptance, demand, and other risks detailed from time to time in OmniVision's Securities and Exchange Commission filings and reports, including, but not limited to, OmniVision's annual report filed on Form 10-K and quarterly reports filed on Form 10-Q. OmniVision expressly disclaims any obligation to update information contained in any forward-looking statement.

OmniVision® and the OmniVision logo are registered trademarks of OmniVision Technologies, Inc. PureCel-S™ is a trademark of OmniVision Technologies, Inc. All other trademarks are the property of their respective owners.

source:http://www.prnewswire.com/ 

Healthcare sector Update: Agilent Technologies (A), Avalanche Biotechnologies (AAVL), AbbVie (ABBV)

A healthy health care sector is giving the ailing — but healing — stock market a booster shot early in 2015.

While the broad Standard & Poor’s 500-stock index heads into Thursday’s trading session down 1.6% for the year, the health care sector — deemed as a “defensive” play in a turbulent market — is a bright light. It is the leading sector in the large-company stock, with a gain of 1.8% in the first four trading days of 2015. Of the 10 sectors, only three are sporting gains this year, with stocks in the consumer staples and utilities sectors in the black.

The big loser this year? It’s no surprise. The beleaguered energy sector, off 4.5%, which has been crushed by the continued plunge in crude prices that began last year. {1}

Below are the sector returns for the 10 major S&P 500 sectors.

Agilent Technologies (NYSE:A) closed gained 2.92% to $40.85, the market capitalization of the stock remained 13.43 billion. YTD trend of the stock was negative -1.21%. The company recently declared the following webcast for the investment community: 33rd Annual J.P. Morgan Healthcare Conference

·         Westin St. Francis Hotel, San Francisco, Calif.

·         Tuesday, Jan. 13, 2015, at 10 a.m. PT

·         Mike McMullen, Agilent president and chief operating officer

Avalanche Biotechnologies Inc (NASDAQ:AAVL) a clinical-stage biotechnology organization focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, recently declared the pricing of its public offering of 2,399,457 shares of its common stock at a public offering price of $59.00 per share, before underwriting discounts, commissions and estimated expenses. 2,009,457 of the shares of common stock are being offered by Avalanche and 390,000 of the shares are being offered by existing stockholders. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 359,918 shares of common stock from Avalanche. The stock, in the current trading session, was at $59.17, with the drop of -1.51%.  Tracking the three months and 6 months trends, the stock was at +89.03% and +111.72%, respectively.

AbbVie Inc. (NYSE:ABBV) enhanced 1.54% and its trading price was $67.97 recently. The volume of the stock was 4.53 million shares and the average volume remained 6.89 million shares. AbbVie Inc. (NYSE:ABBV) in cooperation with Neurocrine Biosciences, Inc. (NBIX), declared positive top-line results from the first of two ongoing Phase 3 clinical trials, designed to evaluate the efficacy and safety of elagolix in premenopausal women with endometriosis. Results from the trial show that after six months of treatment, both doses of elagolix (150 mg once daily and 200 mg twice daily) met the study's co-primary endpoints (p<0.001) of reducing scores of non-menstrual pelvic pain (NMPP) and menstrual pain (or dysmenorrhea), associated with endometriosis, at month three, as well as month six, as measured by the Daily Assessment of Endometriosis Pain scale.

source{1}:http://americasmarkets.usatoday.com/2015/01/08/health-care-sector-gives-market-booster-shot/

Lincoln Builds Momentum from Improved Sales, New Vehicles and Launch in China

DEARBORN, Mich.-Jan. 9, 2015-(TRENDINGGLOBALNEWS)--

The Lincoln Motor Company showed strong progress in 2014, with improved sales, new vehicles, the brand’s launch in China, introduction of Lincoln Black Label and an attention-grabbing ad campaign for the first-ever MKC featuring actor Matthew McConaughey. 

Lincoln finished 2014 with retail sales of 94,474 in North America, a 16 percent increase versus 2013 and the brand’s best sales result since 2008. Further, the brand closed the year strongly, with sales of 26,686 vehicles in the fourth quarter, up 22 percent compared to 2013 and the best fourth quarter since 2007. 

“Lincoln built momentum in 2014 – our new products and advertising campaigns have been warmly received,” said Kumar Galhotra, president of Lincoln. “We launched the brand in China, and are off to a promising start.”

Overall, Lincoln growth outpaced growth in the luxury segment by more than two-to-one.
Driving this double-digit improvement in sales were the first-ever Lincoln MKC, the brand’s first small premium utility vehicle, the Lincoln MKZ midsize premium sedan and the new Lincoln Navigator large premium sports utility vehicle.

Lincoln MKC, which went on sale during the summer, tallied monthly sales of more than 2,000 in October, November and December, finishing the year with a total of 13,077 sold.

Lincoln MKZ sales improved 5 percent, with 2014 sales of 34,009 – its best since 2007. Demand for the MKZ hybrid remained strong, with sales representing 32 percent of total MKZ sales in 2014.

Lincoln Navigator, an additional vehicle to the four all-new Lincoln products promised by 2016, had an immediate impact. With exterior and interior enhancements, sales of the Lincoln Navigator rose 21 percent in 2014 compared to the previous year, doubling its retail share of the large luxury utility segment.

Mirroring the performance of the brand overall in the closing stages of the year, Navigator enjoyed its best fourth quarter since 2007 with sales of 4,545 units, which represents a 71 percent improvement versus last year. Overall, Navigator had sales of 10,433 for 2014.

Stores open in China
 
Following years of careful and exhaustive customer and business research, Lincoln in November and December opened its first nine stores in China – in Beijing, Shanghai, Hangzhou, Qingdao, Guangzhou, Chengdu and Xi’an.

The brand is attracting new luxury customers in China through “The Lincoln Way.” This unique automotive ownership experience emphasizes exemplary and engaging customer service at every step of the process – shopping, buying and owning. 

Lincoln MKZ and Lincoln MKC are the first vehicles on sale in China. Mirroring product launches in the United States, these first two entrants will be followed by Lincoln MKX, Lincoln Navigator and an all-new full-size luxury sedan. 

Lincoln is projected to open 60 stores in 50 cities in China by 2016. 

Lincoln Black Label debuts on MKZ and MKC

Lincoln Black Label, the highest expression of Lincoln quality, design and personal service, is available on Lincoln MKZ and Lincoln MKC. 

The first generation of Lincoln Black Label design themes draws inspiration from a variety of sources – from fashion and food, to luxury travel and architecture. Each was purposely created to make driving a Lincoln a more personal, emotive experience. 

All themes showcase some of the finest automotive interior materials, including Alcantara^®, exclusive leather and crafted woods or woods rare to the automotive industry. 

A total of 32 dedicated Black Label dealers in six states will provide showroom space dedicated to serving Black Label customers. Lincoln plans to expand the network nationwide in late 2015. 

Lincoln announces 10-year partnership with Revel audio
In December, Lincoln announced an exclusive, 10-year collaboration to add the premium sound of Revel^® audio systems to the brand’s lineup.

The next-generation Lincoln MKX will be the first to offer Revel, and is poised to deliver levels of audio enjoyment previously reserved for ultra-high-end home systems.

Revel, Harman’s most premium loudspeaker brand, achieves its acclaimed performance by following a philosophy that embraces science and technology as a means to advance the state of the art in an authentic and natural way.

“The year 2014 was an important one for Lincoln because we made progress in multiple areas. We look forward to further strengthening the brand in 2015 and beyond with more products and initiatives to serve luxury customers in the United States, China and beyond,” said Galhotra. 

About The Lincoln Motor Company

The Lincoln Motor Company is the luxury automotive brand of Ford Motor Company, committed to creating compelling vehicles with an exceptional ownership experience to match. The Lincoln Motor Company is in the process of introducing four all-new vehicles in four years starting with the all-new MKZ in 2013. For more information about The Lincoln Motor Company, please visit media.lincoln.com or www.lincoln.com. Follow us on Facebook at facebook.com/lincoln.

source:http://http://finance.yahoo.com/news/lincoln-builds-momentum-improved-sales-170100353.html/

Array BioPharma To Present At The Annual J.P. Morgan Healthcare Conference

BOULDER, Colo., Jan. 8, 2015 /TRENDINGGLOBALNEWS/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Annual J.P. Morgan Healthcare Conference in San Francisco.  The public is welcome to participate in the conference through a webcast on the Array BioPharma website.    

 

Event:	Annual J.P. Morgan Healthcare Conference
Presenter:	Ron Squarer, Chief Executive Officer, Array BioPharma
Date:	Wednesday, January 14, 2015
Time:	2:00 p.m. Pacific Time
Location:	Westin St. Francis Hotel, San Francisco
Webcast:	www.arraybiopharma.com

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.  Six Phase 3 studies are currently enrolling patients. These programs include two partnered cancer drugs, selumetinib (AstraZeneca) and binimetinib (MEK162 / Novartis).  For more information on Array, please go to www.arraybiopharma.com.

source:http://www.prnewswire.com/ 

Gold Stock News Alert - Allied Nevada Gold Corp. (ANV), Golden Star Resources, Ltd. (GSS), Newmont Mining Corporation (NEM), Gold Resource Corp (GORO)

Gold fell on Thursday as the dollar rose to a 9-year high versus the euro and stock markets climbed more than 2 percent, with minutes from the Federal Reserve's last meeting and steadier oil prices soothing risk aversion.

Spot gold was down 0.4 percent at $1,205.60 an ounce at 1235 GMT, while U.S. gold futures for February delivery were down $4.80 an ounce at $1,205.90.
European shares rose 2.1 percent after minutes from the Federal Reserve's latest policy meeting on Wednesday reassured markets that it was in no hurry to raise interest rates.
Analysts said the minutes held few surprises, with the Fed signalling it would press ahead with plans to begin raising interest rates later this year, but would be "patient" in deciding when the move would come.

A steadier tone to oil prices after recent sharp losses also soothed investors' nerves, helping lift U.S. and European government bond yields off recent lows.{1}

Allied Nevada Gold Corp. (NYSEMKT:ANV), declined -0.31%, and close after touching the figure $0.990, after the news that it has closed the formerly affirmed public offering of shares of ordinary stock and warrants, and assigned 21,750,000 shares and 10,875,000 warrants for gross proceeds of US$21,750,000. Relating to the purchase, investors received one share of our ordinary stock and one half warrant to purchase our ordinary stock for a price of US$1.00.

Golden Star Resources, Ltd. (NYSE:GSS), closed at $0.25, showing the increase of 6.52%, after the company declared that it has filed a technical report, prepared suitable to National Instrument 43-101, regarding a Preliminary Economic Assessment on the development of non-mechanized maneuver at its Prestea mine in Ghana.  This technical report can be accessed under the Company's profile at www.sedar.com and on the Company's website at www.gsr.com. 

Newmont Mining Corporation (NYSE:NEM) dipped 0.89%, and closed at $20.09. It's intraday range was $19.74 - 20.52, and market capitalization was $10.02B. It's average volume is valued $9,689,240, as compared to the current volume of $8,172,339. Newmont Mining Corporation (NYSE:NEM) together with its subsidiaries, acquires, explores for, and produces gold, copper, and silver deposits. The company's assets or operations are placed in the United States, Australia, Peru, Indonesia, Ghana, New Zealand, Mexico, and Suriname. As of December 31, 2013, it had proven and probable gold reserves of approximately 88.4 million ounces and an aggregate land position of approximately 24,000 square miles. The company was founded in 1916 and is headquartered in Greenwood Village, Colorado.

Gold Resource Corp (NYSE:GORO), closed at $3.43, and showed the decrease of 7.53%, soon the company confirmed its monthly instituted dividend of $0.01 per ordinary share for December 2014 allocated on January 23, 2015 to shareholders of record as of January 12, 2015. Gold Resource Corporation is a gold and silver producer with actions in the southern state of Oaxaca, Mexico.

source {1}:http://www.reuters.com/article/2015/01/08/markets-precious-idUSL3N0UN30520150108